

April 26, 2016



Rigel Announces Conference Call and Webcast to Report First Quarter 2016 Financial Results

SOUTH SAN FRANCISCO, Calif., April 26, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2016 financial results after market close on Tuesday, May 3, 2016. Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results.

Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-2939 (international) and using the Conference ID number 97470871. The conference call will also be webcast live and can be accessed from Rigel's website at www.rigel.com. The webcast will be archived and available for replay for 30 days after the call via the Rigel website.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's current clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Rivily, Inc.
Phone: 650.430.3777
mail: susan@rivily.com

Logo - <https://photos.prnewswire.com/prnh/20030226/RIGLLOGO>

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2016-financial-results-300257154.html>

SOURCE Rigel Pharmaceuticals, Inc.